Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer
©2023 The Authors; Published by the American Association for Cancer Research..
PURPOSE: High tumor production of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG), predicted benefit from anti-EGFR therapy for metastatic colorectal cancer (mCRC) in a retrospective analysis of clinical trial data. Here, AREG/EREG IHC was analyzed in a cohort of patients who received anti-EGFR therapy as part of routine care, including key clinical contexts not investigated in the previous analysis.
EXPERIMENTAL DESIGN: Patients who received panitumumab or cetuximab ± chemotherapy for treatment of RAS wild-type mCRC at eight UK cancer centers were eligible. Archival formalin-fixed paraffin-embedded tumor tissue was analyzed for AREG and EREG IHC in six regional laboratories using previously developed artificial intelligence technologies. Primary endpoints were progression-free survival (PFS) and overall survival (OS).
RESULTS: A total of 494 of 541 patients (91.3%) had adequate tissue for analysis. A total of 45 were excluded after central extended RAS testing, leaving 449 patients in the primary analysis population. After adjustment for additional prognostic factors, high AREG/EREG expression (n = 360; 80.2%) was associated with significantly prolonged PFS [median: 8.5 vs. 4.4 months; HR, 0.73; 95% confidence interval (CI), 0.56-0.95; P = 0.02] and OS [median: 16.4 vs. 8.9 months; HR, 0.66 95% CI, 0.50-0.86; P = 0.002]. The significant OS benefit was maintained among patients with right primary tumor location (PTL), those receiving cetuximab or panitumumab, those with an oxaliplatin- or irinotecan-based chemotherapy backbone, and those with tumor tissue obtained by biopsy or surgical resection.
CONCLUSIONS: High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC, including in right PTL disease. AREG/EREG IHC assessment could aid therapeutic decisions in routine practice. See related commentary by Randon and Pietrantonio, p. 4021.
| Errataetall: |
CommentIn: Clin Cancer Res. 2023 Oct 13;29(20):4021-4023. - PMID 37594733 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 29(2023), 20 vom: 13. Okt., Seite 4153-4165 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Williams, Christopher J M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.11.2023 Date Revised 20.03.2024 published: Print CommentIn: Clin Cancer Res. 2023 Oct 13;29(20):4021-4023. - PMID 37594733 Citation Status MEDLINE |
|---|
| doi: |
10.1158/1078-0432.CCR-23-0859 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358653525 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358653525 | ||
| 003 | DE-627 | ||
| 005 | 20240320233224.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/1078-0432.CCR-23-0859 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM358653525 | ||
| 035 | |a (NLM)37363997 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Williams, Christopher J M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.11.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Clin Cancer Res. 2023 Oct 13;29(20):4021-4023. - PMID 37594733 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 The Authors; Published by the American Association for Cancer Research. | ||
| 520 | |a PURPOSE: High tumor production of the EGFR ligands, amphiregulin (AREG) and epiregulin (EREG), predicted benefit from anti-EGFR therapy for metastatic colorectal cancer (mCRC) in a retrospective analysis of clinical trial data. Here, AREG/EREG IHC was analyzed in a cohort of patients who received anti-EGFR therapy as part of routine care, including key clinical contexts not investigated in the previous analysis | ||
| 520 | |a EXPERIMENTAL DESIGN: Patients who received panitumumab or cetuximab ± chemotherapy for treatment of RAS wild-type mCRC at eight UK cancer centers were eligible. Archival formalin-fixed paraffin-embedded tumor tissue was analyzed for AREG and EREG IHC in six regional laboratories using previously developed artificial intelligence technologies. Primary endpoints were progression-free survival (PFS) and overall survival (OS) | ||
| 520 | |a RESULTS: A total of 494 of 541 patients (91.3%) had adequate tissue for analysis. A total of 45 were excluded after central extended RAS testing, leaving 449 patients in the primary analysis population. After adjustment for additional prognostic factors, high AREG/EREG expression (n = 360; 80.2%) was associated with significantly prolonged PFS [median: 8.5 vs. 4.4 months; HR, 0.73; 95% confidence interval (CI), 0.56-0.95; P = 0.02] and OS [median: 16.4 vs. 8.9 months; HR, 0.66 95% CI, 0.50-0.86; P = 0.002]. The significant OS benefit was maintained among patients with right primary tumor location (PTL), those receiving cetuximab or panitumumab, those with an oxaliplatin- or irinotecan-based chemotherapy backbone, and those with tumor tissue obtained by biopsy or surgical resection | ||
| 520 | |a CONCLUSIONS: High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC, including in right PTL disease. AREG/EREG IHC assessment could aid therapeutic decisions in routine practice. See related commentary by Randon and Pietrantonio, p. 4021 | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Amphiregulin |2 NLM | |
| 650 | 7 | |a Epiregulin |2 NLM | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 650 | 7 | |a Panitumumab |2 NLM | |
| 650 | 7 | |a 6A901E312A |2 NLM | |
| 650 | 7 | |a Intercellular Signaling Peptides and Proteins |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a EGFR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Elliott, Faye |e verfasserin |4 aut | |
| 700 | 1 | |a Sapanara, Nancy |e verfasserin |4 aut | |
| 700 | 1 | |a Aghaei, Faranak |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Muranyi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Dongyao |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Isaac |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Zuo |e verfasserin |4 aut | |
| 700 | 1 | |a Shires, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Wood, Henry M |e verfasserin |4 aut | |
| 700 | 1 | |a Richman, Susan D |e verfasserin |4 aut | |
| 700 | 1 | |a Hemmings, Gemma |e verfasserin |4 aut | |
| 700 | 1 | |a Hale, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Bottomley, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Galvin, Leanne |e verfasserin |4 aut | |
| 700 | 1 | |a Cartlidge, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Dance, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Bacon, Chris M |e verfasserin |4 aut | |
| 700 | 1 | |a Mansfield, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Young-Zvandasara, Kathe |e verfasserin |4 aut | |
| 700 | 1 | |a Sudan, Ajay |e verfasserin |4 aut | |
| 700 | 1 | |a Lambert, Katy |e verfasserin |4 aut | |
| 700 | 1 | |a Bibby, Irena |e verfasserin |4 aut | |
| 700 | 1 | |a Coupland, Sarah E |e verfasserin |4 aut | |
| 700 | 1 | |a Montazeri, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Kipling, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Hughes, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Cross, Simon S |e verfasserin |4 aut | |
| 700 | 1 | |a Dewdney, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Pheasey, Leanne |e verfasserin |4 aut | |
| 700 | 1 | |a Leng, Cathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Gochera, Tatenda |e verfasserin |4 aut | |
| 700 | 1 | |a Mangham, D Chas |e verfasserin |4 aut | |
| 700 | 1 | |a Saunders, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Pritchard, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Stott, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Abhik |e verfasserin |4 aut | |
| 700 | 1 | |a Ilyas, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Silverman, Rafael |e verfasserin |4 aut | |
| 700 | 1 | |a Hyland, Georgina |e verfasserin |4 aut | |
| 700 | 1 | |a Sculthorpe, Declan |e verfasserin |4 aut | |
| 700 | 1 | |a Thornton, Kirsty |e verfasserin |4 aut | |
| 700 | 1 | |a Gould, Imogen |e verfasserin |4 aut | |
| 700 | 1 | |a O'Callaghan, Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Nicholas |e verfasserin |4 aut | |
| 700 | 1 | |a Turnbull, Samantha |e verfasserin |4 aut | |
| 700 | 1 | |a Shaw, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Seymour, Matthew T |e verfasserin |4 aut | |
| 700 | 1 | |a West, Nicholas P |e verfasserin |4 aut | |
| 700 | 1 | |a Seligmann, Jenny F |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Shalini |e verfasserin |4 aut | |
| 700 | 1 | |a Shanmugam, Kandavel |e verfasserin |4 aut | |
| 700 | 1 | |a Quirke, Philip |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 29(2023), 20 vom: 13. Okt., Seite 4153-4165 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:20 |g day:13 |g month:10 |g pages:4153-4165 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-23-0859 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 20 |b 13 |c 10 |h 4153-4165 | ||